Predictive factors for time to progression

Univariate analysisRR (95% CI)P
 Age at diagnosis (years), continuous1.00 (0.96–1.04)0.855
 Sex (F vs. M)0.92 (0.50–1.71)0.802
 Durie-Salmon stage at diagnosis (III vs. II)1.29 (0.54–3.08)0.567
 ISS stage at diagnosis (III vs. I-II)0.64 (0.29–1.39)0.257
 Cytogenetics (high risk vs. standard)1.81 (0.80–4.08)0.155
 Immunoglobulin type (others vs. light chain only)2.27 (1.04–4.93)0.039
 Myeloma bone disease on plain radiographs (no vs. yes)1.69 (0.89–3.919)0.107
 Cr at diagnosis (mg/dL), (≥2 vs. < 2)0.61 (0.29–1.28)0.189
 Hb at diagnosis (g/dL), (≥8.5 vs. < 8.5)0.58 (0.31–1.08)0.084
 Ca at diagnosis (mg/dL), (≥10 vs. < 10)1.01 (0.49–2.07)0.985
 β2-microglobulin at diagnosis (mg/dL), (≥5.5 vs. < 5.5)0.60 (0.28–1.31)0.199
 Albumin at diagnosis (mg/dL), (≥3.5 vs. < 3.5)0.58 (0.31–1.08)0.083
 LDH at diagnosis (U/L), (≥450 vs. < 450)1.20 (0.60–2.43)0.607
Multivariate analysisRR (95% CI)P
 Immunoglobulin type (others vs. light chain only)2.01 (0.77–5.24)0.153
 Hb at diagnosis (g/dL), (≥8.5 vs. < 8.5)0.79 (0.40–1.58)0.507
 Albumin at diagnosis (mg/dL), (≥3.5 vs. < 3.5)0.60 (0.30–1.020)0.148
 Pre-ASCT M-MDSC frequency (Low vs. high)0.49 (0.24–0.99)0.045

Ca Calcium, Cr Creatinine, CI Confidence interval, F Female, Hb Hemoglobin, LCD Light chain disease, LDH Lactate dehydrogenase, M Male, TTP Time to progression